Skip to content

Effect of Vaginal Progesterone Treatment on Pregnancy and Newborn Outcomes in Women With Preterm Labor

Perinatal and Neonatal Outcomes of Vaginal Progesterone Supplementation in Women With Preterm Labor

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07523295
Enrollment
60
Registered
2026-04-13
Start date
2025-05-06
Completion date
2025-11-05
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth, Preterm Labor With Intact Membranes

Keywords

low birth weight, Preterm birth, Vaginal progesterone, Dexamethasone, nifedipine

Brief summary

Preterm labor, which occurs when labor starts before 37 weeks of pregnancy, is a major cause of illness and death in newborns. Babies born too early are at higher risk of breathing problems, low birth weight, infections, and other complications. Treatments that safely delay delivery can improve outcomes for both the mother and the baby. The purpose of this clinical study is to determine whether vaginal progesterone treatment can improve pregnancy and newborn outcomes in women who present with preterm labor. The study will compare vaginal progesterone supplementation with conventional care after the initial treatment of preterm labor. The main questions this study aims to answer are: * Does vaginal progesterone increase the latency period (the time from treatment to delivery) in women with preterm labor? * Does vaginal progesterone reduce the chances of preterm birth and low birth weight compared with conventional treatment? This randomized controlled trial will be conducted in the Department of Obstetrics and Gynaecology at Medicare Hospital Multan. A total of 60 pregnant women with singleton pregnancies between 24 and 34 weeks of gestation who present with preterm labor will be enrolled in the study. All participants will first receive standard treatment for preterm labor, including medications to stop contractions (tocolysis with nifedipine for 48 hours) and steroid injections to help mature the baby's lungs. Women whose contractions settle after the initial treatment will then be randomly assigned to one of two groups. One group will receive vaginal progesterone (400 mg daily), while the other group will receive conventional care, which includes counseling and routine pregnancy precautions without progesterone treatment. Participants will continue their assigned management until 36 weeks and 6 days of pregnancy or until delivery occurs. After discharge from the hospital, all women will be followed every two weeks until delivery. Researchers will record important pregnancy and newborn outcomes, including: * Latency period (time from treatment to delivery) * Preterm birth (delivery before 37 weeks of pregnancy) * Birth weight of the newborn By comparing these outcomes between the two groups, the study aims to determine whether vaginal progesterone can safely prolong pregnancy and improve neonatal outcomes in women with preterm labor. The results of this study may help guide future treatment strategies to reduce complications associated with premature birth.

Interventions

Oral Nifedipine 20 mg every 30-minutes for two doses, then 20 mg every 6-hours for 48-hours

DRUGDexamethasone

6 mg intramuscular every 12 hours for a total of four doses

two capsules (200 mg each) applied to the vagina daily till 36-weeks + 6 days or delivery

BEHAVIORALCounseling

Standard counseling and precautionary advice provided after successful tocolysis

Sponsors

Medicare Hospital (Pvt) Limited
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Women with singleton pregnancies (on antenatal scan) * Presenting with pr-term labor * Between 24 - 34 weeks of gestation * Treated successfully with acute tocolysis for 48 hours and received steroids

Exclusion criteria

* Women with multiple pregnancy * Preterm premature rupture of membranes * Cervical dilatation \>3 cm (clinical examination) * Congenital fetal anomalies * Refuse to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Latency PeriodFrom randomization until delivery (up to approximately 13 weeks, depending on gestational age at enrollment).Time from randomization to delivery, measured in days, among women presenting with preterm labor after successful tocolysis.

Countries

Pakistan

Contacts

STUDY_CHAIRMuhammad S Akhtar, FRCOG

Medicare Hospital (Pvt) Limited

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026